Meera Mohan
@MeeraMohanMD
Assistant Professor of Medicine, Myeloma Clinical Faculty @MCW Proud UAMS Alumnus @UAMS myeloma.@AACR/ ASCO Vail 2022 Alumni. #myeloma #MRD#Clinical trial
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/… @UAMSMyeloma
Rewriting Risk: A Data-Driven Look at Myeloma Genetics | Journal of Clinical Oncology #mmsm #bmtsm @JCO_ASCO @DrKrinaPatel ascopubs.org/doi/10.1200/JC…
Thank you for featuring this! Tweetorial below: x.com/RahulBanerjeeM…
1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.
Myeloma Paper of the Day, July 22nd, Suggested by Robert Orlowski (@Myeloma_Doc) @RahulBanerjeeMD @MeeraMohanMD @KRejeski @GKaurMD @DrNikitaMehra @NoopurRajeMD oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM…
#Myeloma Paper of the Day: Viewpoint piece makes evidence-based arguments for use of primary prophylaxis as a safer and simpler approach compared to preemptive IgG-guided immunoglobulin replacement therapy in pts getting bispecific antibodies: pubmed.ncbi.nlm.nih.gov/40690761/. #mmsm
Check our recent work @UAMSMyeloma published @BloodAdvances : Prognostic Impact of Focal Lesion Location and Persistence in Multiple Myeloma: Insights from Serial PET/DWI Imaging #mmsm ➡️ashpublications.org/bloodadvances/… n= 243 multiple myeloma patients followed 9.9 years with serial…
Excellently written @NatureMedicine review, and honestly the best graphics re: CAR-T toxicities (inc. infections & SPMs) that I’ve ever seen 👏 these will be used in slide decks everywhere! Congrats @KRejeski @JoshuaHillMD @MichaelDJain and thanks for writing this! #MMsm #lymsm
🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH
🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH
These woMMEn #myeloma doctors are exceptional physicians and outstanding individuals. They always say yes when I ask them to record a HealthTree University lesson. Consider supporting them in their fundraising endeavors. THANK YOU ladies. #mmsm give.healthtree.org/fundraiser/649…
🧵1/ Real-World Head-to-Head: Cilta-cel vs. Ide-cel in Myeloma 🧬 A prospective biomonitoring study (N=39) dives deep into the biologic and clinical differences between 2 BCMA CAR-Ts: cilta-cel and ide-cel. Results are eye-opening. #mmsm #MedEd #myeloma #MedTwitter #USMIRC…
Recs on prevention of infections during #CARTcell & bispecific antibody Tx in myeloma [6/7/23] @MeeraMohanMD @rajshekharucms @SusanBal9 Nellore @MMBaljevicMD @adsouza_md @DrPappasID @BerdejaJesus @natalie @nsc_natalie @End_myeloma @BrJHaem doi.org/10.1111/bjh.18… #mmsm #IDonc
Effects of IVIG on Infections in Recipients of Teclistamab Tx for Multiple Myeloma: A Multi-Institutional Study [12/7/24] Cheruvalath et al. @MeeraMohanMD #ASH24 Abst 256 ash.confex.com/ash/2024/webpr… #mmsm #IDonc #SuppOnc HT @RahulBanerjeeMD
A thoughtful and nuanced discussion on the results of MIDAS trial #mmsm #bmtsm @rajshekharucms @Eddie_Cliff @MeeraMohanMD podcasts.apple.com/us/podcast/blo…
MIDAS under the Microscope: Check out our special episode unpacking MIDAS trial in newly diagnosed #MultipleMyeloma with @MeeraMohanMD! share.transistor.fm/s/93af17a0
September 6 2025. Kraków welcome at the oldest polish Jagiellonian University 👍 All is free szpiczak2025.jordan.pl
Beautiful paper by my good friend @pkarschnia, amazing to see all your academic progress in the last decade! Highly recommended reading out in @NatRevNeurol on all things CAR-T neurotoxicity - from ICANS to TIAN and MNTs👇
New online! Neurological complications of CAR T cell therapy for cancers bit.ly/4eqkbCe
1/ 🚨New in @Haematologica: Our team evaluated the impact of extramedullary disease (EMD) on toxicity and survival after BCMA CAR-T for multiple myeloma. EMD was associated with more severe toxicity and worse survival. 🧵Read on👇 🔗 haematologica.org/article/view/1…
🧵1/ Our paper is out! A new study from the iStopMM team in @JAMAOnc shows how revising free light chain (FLC) reference intervals can reduce false positives for light chain MGUS (LC-MGUS). Let’s break it down 👇 jamanetwork.com/journals/jamao…